Clinical Trials · NCT07623824
A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With Acromegaly
- Phase
- Phase 3
- Recruitment status
- Not Yet Recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Enrollment
- 154
- Start date
- May 2026
- Locations
- See registry
- Primary endpoint
- The proportion of patients with an IGF-1 index ≤ 1.0